Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-10T09:43:09.499Z Has data issue: false hasContentIssue false

The effects of fenoldopam on renal function in patients undergoing elective aortic surgery

Published online by Cambridge University Press:  16 August 2006

M. Halpenny
Affiliation:
Department of Anaesthesia and Intensive Care Medicine, University College Cork, Dublin, Ireland
C. Rushe
Affiliation:
Department of Anaesthesia and Intensive Care Medicine, Mercy Hospital Cork Dublin, Ireland
P. Breen
Affiliation:
Department of Anaesthesia and Intensive Care Medicine, Beaumont Hospital, Dublin, Ireland
A. J. Cunningham
Affiliation:
Department of Anaesthesia and Intensive Care Medicine, Beaumont Hospital, Dublin, Ireland
D. Boucher-Hayes
Affiliation:
Department of Surgery, Beaumont Hospital, Dublin, Ireland
G. D. Shorten
Affiliation:
Department of Anaesthesia and Intensive Care Medicine, University College Cork, Dublin, Ireland
Get access

Abstract

Background and objective: Postoperative renal impairment is a recognized complication of infrarenal aortic cross-clamping. Our hypothesis was that the renal vasodilating and natriuretic effects of fenoldopam mesylate, a selective dopamine (DA1) agonist, would preserve renal function in patients undergoing elective infrarenal aortic cross-clamping.

Methods: A prospective, randomized, double blind controlled clinical trial was performed. Twenty-eight ASA II-III patients undergoing elective aortic surgery requiring infrarenal aortic cross-clamping were studied. According to random allocation, patients received either fenoldopam (0.1 μg kg−1 min−1) or placebo intravenously prior to surgical skin incision until release of the aortic clamp. Plasma creatinine, creatinine clearance, urinary output, fractional excretion of sodium, and free water clearance were measured: (a) prior to admission to hospital; (b) during the period from insertion of the urinary catheter until application of the aortic cross-clamp; (c) during the period of aortic cross-clamping; (d) 0-4 h, and (e) 4-8 h after release of the clamp and on days 1, 2, 3, and 5 postoperatively.

Results: Fenoldopam (0.1 μg kg−1 min−1) administration was not associated with haemodynamic instability. On application of the aortic cross-clamp creatinine clearance decreased significantly in the placebo (83 ± 20 to 42 ± 29 mLmin−1 (mean ± SD)) (P < 0.01) but not in the fenoldopam group, and this decrease persisted for at least 8 h after release of the cross-clamp (83 ± 20 to 54 ± 33 mLmin−1 (mean ± SD)) (P < 0.05). Plasma creatinine concentration increased significantly from baseline on the first postoperative day in the placebo group (87 ± 12 to 103 ± 28 μmol L−1 (mean ± SD)) (P < 0.01) but not in the fenoldopam group.

Conclusions: These findings are consistent with the hypothesis that fenoldopam possesses a renoprotective effect during and after infrarenal aortic cross-clamping.

Type
Original Article
Copyright
2002 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)